GlassScriptPhysician profile
Carter T Davis
NPI 1407146418
$61,150.04
in general payments reported to CMS, 2019-2025
36 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $354 · 2021: $129 · 2022: $8,769 · 2023: $16K · 2024: $20K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Honoraria: $11K · Food and Beverage: $4,811 · Travel and Lodging: $4,685 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,070 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,612.50 |
| Honoraria | $10,500.00 |
| Food and Beverage | $4,810.50 |
| Travel and Lodging | $4,684.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,070.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $12,335.10 | 2023-2025 | |
| Genentech, INC. | $10,314.95 | 2022-2024 | Venclexta, Columvi, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $9,552.78 | 2022-2025 | |
| Abbvie INC. | $8,236.91 | 2019-2025 | Venclexta, Epkinly |
| Regeneron Pharmaceuticals, INC. | $7,819.89 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $2,637.59 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $2,146.46 | 2022-2023 | Tazverik |
| Genentech USA, INC. | $1,936.42 | 2022-2024 | |
| Celgene Corporation | $1,670.93 | 2019-2025 | Reblozyl, Breyanzi |
| Taiho Oncology, INC. | $1,100.00 | 2024 | |
| Janssen Biotech, INC. | $1,097.90 | 2022-2023 | Imbruvica |
| Kyowa Kirin, INC. | $336.38 | 2022-2023 | Poteligeo |
| Jazz Pharmaceuticals INC. | $259.04 | 2020 | |
| Kite Pharma, INC. | $250.76 | 2023-2025 | Yescarta |
| Beone Medicines USA, INC. | $226.61 | 2025 | Brukinsa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $205.22 | 2021-2022 | |
| Beigene USA, INC. | $196.17 | 2021-2025 | Brukinsa |
| Incyte Corporation | $139.82 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $137.85 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $102.14 | 2022-2023 | |
| Glaxosmithkline, LLC. | $94.96 | 2024 | Ojjaara |
| Genmab U.S., INC. | $58.35 | 2024 | Epkinly |
| Pierre Fabre Pharmaceuticals, INC. | $52.83 | 2025 | Hemangeol |
| Karyopharm Therapeutics INC. | $48.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $45.50 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $32.10 | 2025 | |
| Amgen INC. | $29.94 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $25.82 | 2022 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Epizyme, INC. | $15.51 | 2022 | |
| Gilead Sciences, INC. | $13.49 | 2019 | |
| Daiichi Sankyo INC. | $13.33 | 2023 | Enhertu |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.